Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neo...
| Authors: | ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2024 |
| Country: | España |
| Institution: | Universitat Autònoma de Barcelona |
| Repository: | Dipòsit Digital de Documents de la UAB |
| Language: | English |
| OAI Identifier: | oai:ddd.uab.cat:291402 |
| Online Access: | https://ddd.uab.cat/record/291402 https://dx.doi.org/urn:doi:10.3390/ijms25052627 |
| Access Level: | Open access |
| Keyword: | Breast cancer Neoadjuvant chemotherapy Stromal tumour-infiltrating lymphocytes Tumour-infiltrating immune cells |
| _version_ | 1878740834165194752 |
|---|---|
| author | Arqueros, Cristina|||0000-0003-1249-2324 |
| author2 | Gallardo, Alberto|||0000-0002-2514-2027 Vidal, Silvia|||0000-0002-3909-6682 Osuna Gómez, Rubén|||0000-0003-2875-4405 Tibau Martorell, Ariadna|||0000-0003-0229-6987 Bell, Olga|||0009-0000-2858-6187 Ramon y Cajal, Teresa|||0000-0003-3490-3585 Lerma Puertas, Enrique|||0000-0001-7908-2747 Lobato-Delgado, Bárbara|||0000-0001-6218-5774 Salazar, Juliana|||0000-0002-3581-4499 Barnadas i Molins, Agustí|||0000-0002-0429-1349 |
| author2_role | author author author author author author author author author author |
| author_browse | Arqueros, Cristina|||0000-0003-1249-2324 Barnadas i Molins, Agustí|||0000-0002-0429-1349 Bell, Olga|||0009-0000-2858-6187 Gallardo, Alberto|||0000-0002-2514-2027 Lerma Puertas, Enrique|||0000-0001-7908-2747 Lobato-Delgado, Bárbara|||0000-0001-6218-5774 Osuna Gómez, Rubén|||0000-0003-2875-4405 Ramon y Cajal, Teresa|||0000-0003-3490-3585 Salazar, Juliana|||0000-0002-3581-4499 Tibau Martorell, Ariadna|||0000-0003-0229-6987 Vidal, Silvia|||0000-0002-3909-6682 |
| author_facet | Arqueros, Cristina|||0000-0003-1249-2324 Gallardo, Alberto|||0000-0002-2514-2027 Vidal, Silvia|||0000-0002-3909-6682 Osuna Gómez, Rubén|||0000-0003-2875-4405 Tibau Martorell, Ariadna|||0000-0003-0229-6987 Bell, Olga|||0009-0000-2858-6187 Ramon y Cajal, Teresa|||0000-0003-3490-3585 Lerma Puertas, Enrique|||0000-0001-7908-2747 Lobato-Delgado, Bárbara|||0000-0001-6218-5774 Salazar, Juliana|||0000-0002-3581-4499 Barnadas i Molins, Agustí|||0000-0002-0429-1349 |
| author_role | author |
| collection | Dipòsit Digital de Documents de la UAB |
| description | Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry. TIICs markers (CD4, CD8, CD20, CD1a, and CD68) were assessed immunohistochemically. High sTILs were significantly associated with pathological complete response (pCR; p = 0.048) and event-free survival (EFS; p = 0.027). High-CD68 cells were significantly associated with pCR in triple-negative (TN, p = 0.027) and high-CD1a cells with EFS in luminal-B (p = 0.012) BC. Cluster analyses of TIICs revealed two groups of tumours (C1 and C2) that had different immune patterns and clinical outcomes. An immunoscore based on clinicopathological variables was developed to identify high risk (C1) or low-risk (C2) patients. Additionally, cluster analyses revealed two groups of tumours for both luminal-B and TNBC. Our findings support the association of sTILs with pCR and show an immunological component in a subset of patients with HER2-negative BC. Our immunoscore may be useful for future escalation or de-escalation treatments. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_da376a8a2f1725bfab8b4e1d1768b28d |
| institution | Universitat Autònoma de Barcelona |
| instname_str | Universitat Autònoma de Barcelona |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:ddd.uab.cat:291402 |
| publishDate | 2024 |
| publishDateSort | 2024 |
| reponame_str | Dipòsit Digital de Documents de la UAB |
| spelling | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy Arqueros, Cristina|||0000-0003-1249-2324 Gallardo, Alberto|||0000-0002-2514-2027 Vidal, Silvia|||0000-0002-3909-6682 Osuna Gómez, Rubén|||0000-0003-2875-4405 Tibau Martorell, Ariadna|||0000-0003-0229-6987 Bell, Olga|||0009-0000-2858-6187 Ramon y Cajal, Teresa|||0000-0003-3490-3585 Lerma Puertas, Enrique|||0000-0001-7908-2747 Lobato-Delgado, Bárbara|||0000-0001-6218-5774 Salazar, Juliana|||0000-0002-3581-4499 Barnadas i Molins, Agustí|||0000-0002-0429-1349 Breast cancer Neoadjuvant chemotherapy Stromal tumour-infiltrating lymphocytes Tumour-infiltrating immune cells Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry. TIICs markers (CD4, CD8, CD20, CD1a, and CD68) were assessed immunohistochemically. High sTILs were significantly associated with pathological complete response (pCR; p = 0.048) and event-free survival (EFS; p = 0.027). High-CD68 cells were significantly associated with pCR in triple-negative (TN, p = 0.027) and high-CD1a cells with EFS in luminal-B (p = 0.012) BC. Cluster analyses of TIICs revealed two groups of tumours (C1 and C2) that had different immune patterns and clinical outcomes. An immunoscore based on clinicopathological variables was developed to identify high risk (C1) or low-risk (C2) patients. Additionally, cluster analyses revealed two groups of tumours for both luminal-B and TNBC. Our findings support the association of sTILs with pCR and show an immunological component in a subset of patients with HER2-negative BC. Our immunoscore may be useful for future escalation or de-escalation treatments. https://ddd.uab.cat/record/291402 https://dx.doi.org/urn:doi:10.3390/ijms25052627 |
| spellingShingle | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy Arqueros, Cristina|||0000-0003-1249-2324 Breast cancer Neoadjuvant chemotherapy Stromal tumour-infiltrating lymphocytes Tumour-infiltrating immune cells |
| title | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| title_full | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| title_fullStr | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| title_full_unstemmed | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| title_short | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| title_sort | Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy |
| topic | Breast cancer Neoadjuvant chemotherapy Stromal tumour-infiltrating lymphocytes Tumour-infiltrating immune cells |
| topic_facet | Breast cancer Neoadjuvant chemotherapy Stromal tumour-infiltrating lymphocytes Tumour-infiltrating immune cells |
| url | https://ddd.uab.cat/record/291402 https://dx.doi.org/urn:doi:10.3390/ijms25052627 |